Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Dermata Therapeutics, Inc. - Common Stock
(NQ:
DRMA
)
1.860
-0.510 (-21.52%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Dermata Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
December 24, 2025
Via
ACCESS Newswire
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
December 04, 2025
Via
ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 14, 2025
Via
ACCESS Newswire
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
October 02, 2025
Via
ACCESS Newswire
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
September 18, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
September 17, 2025
Via
ACCESS Newswire
Life Science Virtual Investor Forum Agenda Announced for September 18th
September 16, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th
September 16, 2025
Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Dermata to Present on BioPub on January 31, 2025
January 29, 2025
Via
ACCESS Newswire
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
December 16, 2024
Via
ACCESSWIRE
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
September 10, 2025
Via
ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 13, 2025
Via
ACCESS Newswire
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
July 08, 2025
Via
ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 14, 2025
Via
ACCESS Newswire
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
April 15, 2025
Via
ACCESS Newswire
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
December 10, 2024
Via
ACCESSWIRE
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
December 03, 2024
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 13, 2024
Via
ACCESSWIRE
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
March 27, 2025
Via
ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
March 17, 2025
Via
ACCESS Newswire
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
February 25, 2025
Via
ACCESS Newswire
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
January 22, 2025
Via
ACCESS Newswire
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
January 21, 2025
Via
ACCESS Newswire
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
November 15, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Sciences Investor Forum Agenda Announced for November 14th
November 12, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
November 11, 2024
– Dermata Therapeutics invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com –
From
Virtual Investor Conferences
Via
GlobeNewswire
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
October 08, 2024
Via
ACCESSWIRE
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
September 17, 2024
Via
ACCESSWIRE
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
September 16, 2024
Via
ACCESSWIRE
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
September 05, 2024
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
